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Introduction: Donation after circulatory death (DCD) could substantially improve
donor heart availability. However, warm ischemia prior to procurement is of particular
concern for cardiac graft quality. We describe a rat model of DCD with in-situ
ischemia in order to characterize the physiologic changes during the withdrawal period
before graft procurement, to determine effects of cardioplegic graft storage, and to
evaluate the post-ischemic cardiac recovery in comparison with an established ex-situ
ischemia model.
Methods: Following general anesthesia in male, Wistar rats (404 ± 24 g, n = 25),
withdrawal of life-sustaining therapy was simulated by diaphragm transection. Hearts
underwent no ischemia or 27min in-situ ischemia and were explanted. Ex situ, hearts
were subjected to a cardioplegic flush and 15min cold storage or not, and 60min
reperfusion. Cardiac recovery was determined and compared to published results of
an entirely ex-situ ischemia model (n = 18).
Results: In donors, hearts were subjected to hypoxia and hemodynamic changes,
as well as increased levels of circulating catecholamines and free fatty acids prior to
circulatory arrest. Post-ischemic contractile recovery was significantly lower in the in-situ
ischemia model compared to the ex-situmodel, and the addition of cardioplegic storage
improved developed pressure-heart rate product, but not cardiac output.
Conclusion: The in-situ model provides insight into conditions to which the heart is
exposed before procurement. Compared to an entirely ex-situ ischemia model, hearts
of the in-situ model demonstrated a lower post-ischemic functional recovery, potentially
due to systemic changes prior to ischemia, which are partially abrogated by cardioplegic
graft storage.
Keywords: cardiac ischemia-reperfusion, experimental rat models, donation after circulatory death (DCD), ex-situ
ischemia, in-situ ischemia, heart transplantation
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INTRODUCTION
Grafts obtained from donation after circulatory death (DCD)
could substantially improve donor heart availability, which is a
major issue in heart transplantation. However, concerns related
to graft quality persist as they are subjected to a period of warm
global ischemia before procurement. Despite excellent clinical
outcomes in DCD heart transplantation (1, 2), further expansion
of the donor pool requires the optimization of protocols to
guarantee optimal graft quality.
In order to evaluate strategies for improving current DCD
protocols, the choice of the most appropriate and clinically
relevant animal models is essential. The ex-situ working rat heart
system is a well-established experimental model that has been
used in several studies to investigate cardioprotective strategies
and ischemic tolerance in the context of DCD (3–8). With this
model, the pre-ischemic and ischemic phases are carried out in
the ex-situ heart preparation. This model allows tight control
of experimental conditions, such as the precise timing of warm
ischemic onset, and pre-ischemic energy substrate availability.
Further, the ex-situ preparation permits detailed functional and
biochemical assessment prior to warm ischemia and reperfusion.
However, this model lacks the physiological changes that occur
after the withdrawal of life sustaining therapy (WLST) in the
donor. (9, 10). This is of particular importance in DCD, as
the heart is not only exposed to warm ischemia, but also to a
potentially damaging pre-ischemic phase prior to procurement.
The consideration of this pre-ischemic phase and the
simulation of the DCD process in a donor is receiving more
and more attention in the field, and several in-situ rat models
have recently been developed (11–20). However, no standard
protocol is available; for example, initiation of the DCD process
can be simulated in different ways; by simply terminating the
ventilatory support (14, 15, 17), by terminating ventilatory
support in combination with a tracheal clamp (12, 13), with or
without the addition of respiratory muscle paralysis (11, 16),
or by the transection of the diaphragm (19, 20). Furthermore,
not all protocols employ the same definition of the start of
warm ischemia. For example, some measure cardiac asystole
by electrocardiogram (11) while others define the beginning
of ischemia when the peak systolic pressure drops below 30
mmHg or asystole (12, 13), or when the blood pressure was
non-pulsatile or the mean arterial pressure less than 30 mmHg
(14, 17). As such, strict comparison among varying pre-clinical
models requires careful interpretation, but when possible, it may
aid in advancing our understanding of the pathophysiologic
processes involved.
Post-ischemic cardiac function, as well as the efficacy of
protective strategies may not only be influenced by ischemia
itself, but also by pre-ischemic conditions (9), which can alter
Abbreviations: DCD, donation after circulatory death; dP/dt max, maximum first
derivative of left ventricular pressure; dP/dt min, minimum first derivative of
left ventricular pressure; EPO, erythropoietin; ES, ischemic ex-situ model; FFA,
free fatty acids; FWIT, functional warm ischemic time; GTN, glyceryl trinitrate;
IS, ischemic in-situ model; IS+, ischemic in-situ model with cardioplegia; min,
minutes; PCO2, partial carbon dioxide pressure; PO2, partial oxygen pressure;
WLST, withdrawal of life sustaining therapy.
cardiac metabolism upon reperfusion. Studies in pre-clinical
models have shown that the phase betweenWLST and ischemia is
characterized by hemodynamic instability, pressure and volume
overload, significant drop up to cessation of arterial pulsatility
and subsequent systemic responses that lead to catecholamine
release (9, 10, 17). Besides influencing cardiac rhythm and
contractility, catecholamines are also known to trigger the release
of free fatty acids (FFA) into the circulation (21). Although
increased pre-ischemic concentrations of FFA have not yet
been measured in DCD, our group has demonstrated that
pre-ischemic substrate availability, e.g., acute expose to high
circulating fatty acids, can negatively affect post-ischemic cardiac
recovery (22).
As interventions prior to circulatory death are limited for
ethical reasons, strategies to reduce post-ischemic cardiac
dysfunction that are applied after heart procurement hold
much promise, particularly the initial reperfusion after warm
ischemia. The majority of centers performing DCD heart
transplantation are currently using St. Thomas’ N◦2 cardioplegia
or Bretschneider histidine–tryptophan–ketoglutarate
(HTK) crystalloid solution (Custodiol) supplemented with
erythropoietin and glyceryl-trinitrate (23). However, the impact
of perfusion with cold preservation solutions and this brief
period of cold ischemia on post-ischemic functional recovery has
not yet been investigated.
With the current study, we aimed to establish a clinically
relevant in-situ ischemia rat model of DCD in our lab,
to characterize the period between WLST until the end of
functional, warm ischemia, and to evaluate the effects of cold
cardioplegic storage in the in-situ model. Furthermore, we
evaluated and compared post-ischemic cardiac recovery with
isolated hearts from a published ex-situ ischemiamodel (6), using
new measurements and analyses.
MATERIALS AND METHODS
Ethics Statement
All experimental procedures were performed in compliance with
the European Convention for Animal Care and approved by the
Swiss animal welfare authorities and the Ethics Committee for
Animal Experimentation, Berne, Switzerland (Veterinärdienst
des Kantons Bern; BE40/15, BE103/17 and BE104/18). Surgery
was performed under anesthesia, and all efforts were made to
minimize animal suffering.
Animals
MaleWistar rats (Janvier Labs, Le Genest-Saint-Isle, France) were
housed in groups under standard conditions with a 12 h light-
dark cycle at a controlled room temperature, humidity and ad
libitum access to water and food (KLIBA NAFAG, GRANOVIT
AG, Kaiseraugst, Switzerland). Rats weighing 375–425 g and aged
11–12 weeks were chosen to represent young-adult, human DCD
heart donors and to ensure mature cardiac metabolism (24, 25).
A total of 43 rats were used in this study, and 7 rats over
6 experimental groups were excluded due to technical issues
in cardiac function recording or long episodes of fibrillation
Frontiers in Cardiovascular Medicine | www.frontiersin.org 2 January 2021 | Volume 7 | Article 596883
Arnold et al. Cardiac DCD: in-situ/ex-situ Models
(Supplementary Figure 3). The total number of rats included in
each group are reported in Tables 1, 2.
Experimental Set Up
We established and characterized an in-situ rat model of DCD in
our lab. With this model, four different experimental conditions
were investigated: 0 and 27min in-situ ischemia (IS), and 0 and
27min in-situ ischemia with the addition of cardioplegia and cold
storage (IS+). Post-ischemic cardiac recovery was determined
following heart explantation and perfusion under normothermic
conditions for 60min. Cardiac recovery was also compared to
recently published corresponding ischemic groups generated
with a purely ex-situ ischemia model (ES) (6) following further
measurements and analyses. The protocols of all six experimental
groups are presented in Figure 1. Hearts of all six experimental
TABLE 1 | Baseline characteristics of ex-situ hearts.
NI-ES I-ES
Number of hearts 8 7
Body weight (g) 406 ± 31 390 ± 19
Heart rate
(beats * min−1 )
258 ± 41 255 ± 39
Left ventricular work
(mmHg*beats*min−1*103)
33 ± 4 34 ± 5
Developed pressure
(mmHg)
129 ± 13 132 ± 10
dP/dtmin
(mmHg*s−1*103)
−4.5 ± 1.0 −4.3 ± 0.6
dP/dtmax
(mmHg*s−1*103)
4.4 ± 0.6 4.3 ± 0.4
Cardiac output
(mL*min−1 )
63 ± 11 67 ± 11
Coronary flow
(mL*min−1 )
32 ± 5 32 ± 4
Cardiac functional parameters were obtained during the 20-min perfusion (average of
10 and 20min values) before ischemia in isolated, working hearts. dP/dt max, maximum
first derivative of LV pressure; dP/dt min, minimum first derivative of LV pressure; I-ES,
ischemic ex-situ model; NI-ES, non-ischemic ex-situ model.
TABLE 2 | Baseline characteristics of in-situ hearts.
NI-IS NI-IS+ I-IS I-IS+
Number of hearts 5 5 6 5
Body weight
(g)
397 ± 24 394 ± 15 418 ± 26 405 ± 28
Heart rate
(beats * min−1 )
224 ± 9 234 ± 43 249 ± 37 255 ± 12
Peak systolic pressure
(mmHg)
95 ± 15 93 ± 10 107 ± 11 104 ± 5
Pulse pressure
(mmHg)
29 ± 16 17 ± 11 31 ± 13 29 ± 5
Heart rate, peak systolic pressure and pulse pressure were measured before withdrawal
of life sustaining therapy in vivo. I-IS, ischemic in-situ model; I-IS+, ischemic in-situ model
with cardioplegia; NI-IS, non-ischemic in-situ model; NI-IS+, non-ischemic in-situ model
with cardioplegia.
groups were then reperfused ex situ to determine post-ischemic
cardiac recovery.
Heart Preparation for Ischemia in-situ
Surgical anesthesia was induced in rats with an intraperitoneal
injection of 78 mg/kg ketamine (Narketan R©, Vetoquinol
AG, Bern, Switzerland), 7.2 mg/kg xylazine (Xylapan R©,
Vetoquinol AG, Bern, Switzerland), and 1.2 mg/kg acepromazine
(Prequillan, Fatro AG, Bologna, Italy). Arterial oxygen saturation
(SaO2) was monitored using a toe-clip pulse oximeter (AD
Instruments, Spechbach, Germany). Animals received 100%
oxygen via a face mask and flow adjustments were made to keep
SaO2 between 95 and 99%.When the hind-paw withdrawal reflex
could not be elicited after toe pinch, a catheter was inserted into
the right common carotid artery and connected to a pressure
transducer for continuous recording of blood pressure and
heart rate. Seven hundred and fifty U.I./kg of sodium heparin
(Liquemin R©, Drossapharm AG, Arlesheim, Switzerland) were
injected through this catheter, which also served as blood
sampling port. Withdrawal of life sustaining therapy was
simulated by asphyxiation through transection of the diaphragm.
Functional warm ischemic time (FWIT) was considered to
start when the peak systolic pressure dropped below 50 mmHg.
Circulatory arrest was declared when the pulse pressure was
lower than 3 mmHg. Body temperature was measured by
introducing a sensor tip thermometer into the thoracic cavity
and temperature was kept between 36.6 and 37.2◦C using a
heating lamp (if required). After 27min of ischemia, all hearts
were explanted, and aortae cannulated in the same isolated heart
system used with the ex-situ ischemia model for the reperfusion
period where cardioplegia was administered following the
current clinical practice: hearts were flushed with 7mL ice cold
St. Thomas’ N◦2 cardioplegic solution supplemented with 100
mg/mL glyceryl trinitrate (GTN; Nitroglycerin Bioren, Sintetica,
Mendrisio, Switzerland) and 5,000 U/L erythropoietin (EPO;
Eprex, Janssen, Berchem, Belgium) (26) at a constant pressure
of 60 mmHg and then statically stored for a total of 15min
immersed in ice-cold St. Thomas’ N◦2 cardioplegia. FWIT was
considered to end with the initiation of the cardioplegic flush.
Heart Preparation for Ischemia ex-situ
Surgical anesthesia was induced in rats with an intraperitoneal
injection of 100 mg/kg ketamine (Narketan R©, Vetoquinol
AG, Bern, Switzerland), and 10 mg/kg xylazine (Xylapan R©,
Vetoquinol AG, Bern, Switzerland). Adequate depth of
anesthesia was confirmed by absence of the hind-paw withdrawal
reflex. Hearts were then rapidly excised, placed in ice-cold
phosphate-buffered saline, and working- mode preparations
were established. Isolated, working rat hearts were prepared
as previously described (5, 6). Briefly, hearts were aerobically
perfused with a modified Krebs-Henseleit buffer containing
1.25mM Ca2+, 11mM glucose, 1.2mM palmitate bound to
3% BSA and 0.5mM lactate oxygenated with 95% O2-5% CO2
for a pre-ischemic period of 20min at a constant pressure of
80 mmHg. Ischemia of 27min was initiated and terminated by
clamping and unclamping of the pre- and after- load perfusion
lines, respectively. During the ischemic period, the heart was
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FIGURE 1 | Perfusion protocols for all experimental groups using the ex-situ model and the in-situ model with and without cardioplegic storage. Ex-situ ischemia was
induced by clamping pre- and afterload lines. In-situ ischemia/functional warm ischemia (FWIT) was induced by simulating withdrawal of life sustaining therapy
(WLST). FWIT start was defined as peak systolic pressure <50 mmHg and FWIT end was defined as initial coronary perfusion (with cardioplegia or physiologic buffer).
immersed in a glucose- and palmitate-free Krebs-Henseleit
buffer at 37◦C.
Protocol for Post-ischemic Heart Perfusions (Both
Models)
Ischemic and non-ischemic hearts from both models were
reperfused for a total of 60min using a modified Krebs-
Henseleit buffer containing 1.25mM Ca2+ and 11mM glucose.
Hearts remained unloaded during the first 10min. During this
time, the left atria of hearts from the in-situ model were
cannulated. The perfusion was then switched to working mode
for another 50min. During the 60min reperfusion, perfusate
was recirculating, except the first minute of reperfusion in hearts
obtained with the in-situmodel, when cardioplegia or blood was
washed out and discarded. All hearts were maintained at 37◦C
with an aortic pressure of 60 mmHg. At the end of the protocol,
hearts were immediately frozen in liquid nitrogen and stored
at−80◦C.
Assessment of Cardiac Function
Intraventricular cardiac pressure was measured using a micro-
tip pressure catheter (Millar, Houston, USA) placed in the
left ventricle. Perfusate flow was measured using flow probes
(Transonic Systems Inc., Ithaca, USA) placed in pre- and after-
load lines. Data were continuously recorded using a PowerLab
data acquisition system (ADInstruments, Spechbach, Germany).
Blood and Perfusate Sampling
During the in-situ ischemia protocol, blood analysis was
performed before withdrawal, during the withdrawal phase
(FWIT and cardiac arrest time points) and, for the ischemic
hearts, at the end of the 27min in-situ ischemia. Blood samples
were obtained from the carotid artery (arterial blood) prior
to heart procurement, and from the chest cavity after heart
procurement at end-ischemia (mixed arterial-venous blood).
Samples were used for blood gas analysis (see details in the
Supplementary Material) and the remainder was transferred to
lithium heparin tubes and centrifuged at 2,000g for 5min. Plasma
was stored at−80◦C.
During post-ischemic heart perfusions, coronary effluent and
circulating perfusate were sampled at multiple time points.
Samples were stored at−80◦C.
Additional Methods
The following methods and materials are described in detail
in the Supplementary Material: measurement of blood gas,
circulating factors and measurement of tissue water content.
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Statistical Analysis
Values are reported as mean ± standard deviation or as median,
25–75 percentiles and range (box-and-whiskers). Statistical
analyses were performed with GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA). The Kruskal-Wallis
test was performed for an overview of differences between
experimental groups and, when significant overall results
were observed, comparisons between groups of interest were
performed with Mann-Whitney analyses. Two-tailed p-values
were adjusted for multiple comparisons (modified, sequential,
rejective Bonferroni procedure) (27). Corrected p-values are
reported and considered statistically significant if <0.05.
RESULTS
Baseline Characteristics
Baseline characteristics for the ischemic ex-situ and in-situ
groups are represented in Tables 1, 2, respectively. No difference
in baseline characteristics among experimental groups was
observed in either the ex-situ or the in-situmodel.
Withdrawal Phase (in-situ Ischemia Model)
The average time from WLST to FWIT start was 1.0 ± 0.6min.
For hearts that underwent ischemia, mean time from FWIT start
to circulatory arrest was 1.9 ± 0.9min. No difference among
experimental groups was observed (Supplementary Table 1).
Peak systolic pressure in rats dropped significantly afterWLST
and was, per definition, 50 mmHg at FWIT start (p < 0.05;
Figure 2A). A hyperdynamic phase was observed for heart rate
and pulse pressure. Heart rate increased after WLST (p < 0.05)
before it finally dropped (Figure 2B). Similarly, pulse pressure
appeared to increase after WLST, however this change did
not reach statistical significance. Subsequently, pulse pressure
continuously dropped to 3 mmHg, at which time circulatory
arrest was declared (p < 0.05 hyperdynamic phase vs. FWIT and
FWIT vs. cardiac arrest; Figure 2C).
Blood O2 saturation immediately dropped after WLST and
was below the detection level (<30%) for all subsequent
measurement time points (Figure 3A). A similar steep decline
was observed for the partial pressure of oxygen (PO2), as shown
in Figure 3B. Partial pressure of carbon dioxide (PCO2) at the
pre-withdrawal of life sustaining therapy time point already
indicated hypercapnia (63.3 ± 16.4 mmHg). PCO2 after WLST
increased and reached the upper detection threshold (>150
mmHg) at the end of ischemia (p < 0.05 cardiac arrest vs.
end-ischemia; Figure 3B).
Blood pH dropped significantly from pre-withdrawal of life
sustaining therapy to FWIT (p < 0.05), and remained stable
from FWIT to cardiac arrest. At the end of 27min ischemia, pH
further decreased to a profound acidosis (p < 0.05; Figure 3C)
with a concomitant increase in blood lactate concentration
(Figure 3C).
FIGURE 2 | Functional parameters during in-situ/withdrawal phase. (A) Peak systolic pressure (PSP) (B) heart rate (HR) (C) pulse pressure (PP). CA, circulatory arrest;
FWIT, functional warm ischemia start; HD, hyperdynamic phase; pre-W, pre-withdrawal of life sustaining therapy. Data are expressed as mean ± standard deviation.
Statistical analyses were only performed between consecutive time points. ◦p < 0.05 vs. corresponding previous time point. n = 10–21/time point.
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Both blood calcium and potassium concentrations increased,
being highest at end ischemia (Figure 3D). Blood sodium,
chloride and glucose concentrations are presented in
Supplementary Figure 1.
Concentrations of catecholamines in blood are represented
in Figure 3E; adrenaline and noradrenaline both increased at
FWIT to cardiac arrest (p < 0.05 for both; Figure 3E). Peak
concentrations were reached at end ischemia.
Blood free fatty acid concentrations peaked before withdrawal
and dropped significantly by FWIT (p < 0.05; Figure 3F).
Post-ischemic Functional Recovery
Post-ischemic functional recovery is presented in Figure 4 and
Supplementary Figure 2. In general, left ventricular work at
the end of reperfusion (Figure 4A) was lower after ischemia
compared to the corresponding non-ischemic groups, reaching
statistical significance for IS and ES groups (p < 0.05 for
both). Furthermore, among non-ischemic hearts, left ventricular
work tended to be lower in ES vs. IS and IS+ hearts,
reaching statistical significance between IS and ES groups (p
< 0.05). However, among ischemic hearts, left ventricular
work was significantly decreased in IS vs. ES hearts (p <
0.05). Thus, recovery expressed as percentage of corresponding
non-ischemic group, was significantly lower in IS vs. ES (45
± 13% vs. 78 ± 9%, respectively, p < 0.05). Interestingly,
no differences were observed between IS+ and ES hearts
for both absolute values and percentage recovery of left
ventricular work.
Similar patterns were observed for contractility rate (dP/dt
max) and relaxation rate (dP/dt min) at 60min of reperfusion
(Figures 4B,C); however, although a tendency for improved
recovery was observed with IS+ compared to IS hearts, the
FIGURE 3 | Blood parameters during in-situ/withdrawal phase. (A) Oxygen saturation (SO2) (B) partial oxygen and carbon dioxide pressure (PO2 and PCO2) (C) blood
pH and lactate (D) blood calcium (Ca2+) and potassium (K+) (E) blood adrenaline and noradrenaline (F) blood free fatty acids. CA, circulatory arrest; EI, end-ischemia;
FWIT, functional warm ischemia start; ND, below detection limit; pre-W, pre-withdrawal of life sustaining therapy. Data are expressed as mean ± standard deviation.
Statistical analyses were only performed between consecutive time points. ◦ or 2 p < 0.05 vs. corresponding previous time point. n = 8–21/time point.
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FIGURE 4 | Post-ischemic cardiac function at 60min reperfusion. (A) LV work (left ventricular work: heart rate*developed pressure) (B) dP/dt max (maximum first
derivative of LV pressure) (C) dP/dt min (minimum first derivative of LV pressure) (D) CO (cardiac output). Data are expressed as median, 25–75 percentiles, and range;
numbers indicate percentage of corresponding non-ischemic value. *p < 0.05, +p < 0.05 vs. ES. ES, ex-situ model; IS, in-situ model; IS+, in-situ model with
cardioplegia; RP, reperfusion; n = 5–8 per group.
percent recovery for these hearts remained significantly lower
than that of ES hearts.
The results of cardiac output (Figure 4D) were also similar;
however, the addition of cardioplegia did not appear to
improve recovery.
Vascular Parameters
During early reperfusion (5min), coronary flow was significantly
lower in ischemic vs. corresponding non-ischemic hearts in
the in-situ model (p < 0.05 for IS and IS+), but not in
the ex-situ model (Figure 5A). Among non-ischemic groups,
coronary flow was significantly increased in the IS+ hearts
compared to the ES hearts (p < 0.05; Figure 5A), suggesting
greater vasodilation. While in ischemic hearts, coronary flow was
significantly decreased in IS and IS+ hearts compared with ES
hearts (p < 0.05 for both; Figure 5A), and cardioplegic storage
did not affect coronary flow.
Similarly, after 60min reperfusion, coronary flow was
significantly lower in ischemic vs. the corresponding non-
ischemic hearts in the in-situ model (p < 0.05 for IS and
IS+), but not in the ex-situ model (Figure 5B). Among ischemic
hearts, coronary flow was significantly lower in the in-situmodel
compared with the ex-situmodel (p < 0.05 for both; Figure 5A),
and cardioplegic storage did not affect coronary flow.
Organ edema was significantly increased with ischemia in
all the groups compared to their corresponding non-ischemic
groups (p < 0.05 for all; Figure 5C). No differences among either
ischemic groups or non-ischemic groups were observed.
Circulating Factors
At 60min reperfusion, cardiac troponin I was significantly
higher in all ischemic groups compared to their corresponding
non-ischemic groups (p < 0.05 for all), and no differences were
observed among ischemic or non-ischemic groups (Figure 6A).
A similar pattern was observed for heart-type fatty acid
binding protein (p < 0.05 for all; Figure 6B).
Cytochrome c, a marker of mitochondrial damage, tended
to be increased in all ischemic groups compared to their
corresponding non-ischemic groups, but reached statistical
significance only for ES and IS+ hearts (p < 0.05 for both;
Figure 6C). No differences were observed among ischemic or
non-ischemic groups.
DISCUSSION
For the safe expansion of DCD heart transplantation, preclinical
research models are required to help optimize current clinical
protocols. Although large animalmodels, such as porcinemodels,
are necessary to test clinical relevance, studies in smaller animal
models, such as rats, are more easily manageable with respect
to both technical and financial aspects, thereby allowing only
the most promising approaches to proceed with testing in
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FIGURE 5 | Vascular parameters. (A) Coronary flow at 5min reperfusion (B) Coronary flow at 60min reperfusion (C) Tissue water content at 60min reperfusion. Data
are expressed as median, 25–75 percentiles, and range; numbers indicate percentage of corresponding non-ischemic value. *p < 0.05, +p < 0.05 vs. ES. ES, ex-situ
model; IS, in-situ model; IS+, in-situ model with cardioplegia; RP, reperfusion; n = 5−8 per group.
FIGURE 6 | Circulating factors. (A) Cardiac troponin I (cTnI) release at 60min reperfusion (B) Heart-type fatty acid binding protein (H-FABP) release at 60min
reperfusion (C) Cytochrome c (Cyt c) release at 10min reperfusion. Data are expressed as median, 25–75 percentiles and range. *p < 0.05. ES, ex-situ model; IS,
in-situ model; IS+, in-situ model with cardioplegia; RP, reperfusion; n = 5–8 per group.
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larger animal models. We describe an in-situ ischemia rat
model of DCD, with characterization of the withdrawal phase,
investigation of the effects of a brief period of cold cardioplegia,
and comparison of cardiac recovery with a completely ex-situ
ischemia model. Simulation of withdrawal of life sustaining
therapy in the in-situ model of DCD induced a hyperdynamic
cardiac phase and an elevation in plasma catecholamines before
circulatory arrest, which is in agreement with other pre-
clinical models of DCD (9, 10, 17). Interestingly, we report
that circulating concentrations of FFA are also increased,
which is of particular importance as high concentrations
of pre-ischemic fatty acids are associated with substantially
reduced contractile recovery and greater mitochondrial damage
(22). Significantly lower post-ischemic contractile recovery was
observed with in-situ ischemia (IS) compared to ex-situ ischemia
(ES). However, the addition of a brief period of cold ischemia
with cardioplegia did not further reduce recovery, rather it
provided an improvement in left ventricular work compared
to in-situ ischemia without cardioplegia. However, cardioplegia
was not able to rescue decreased post-ischemic coronary flow,
which was significantly lower in both in-situ conditions vs. ES,
suggesting greater endothelial dysfunction/damage. Importantly,
no difference between models was observed for markers of cell
death or mitochondrial damage. In summary, we conclude that
the choice of experimental model can affect cardiac recovery
in a variable-specific manner and that models for cardiac DCD
require careful selection according to the particular research
focus (Table 3).
In the in-situ model of DCD, hearts are exposed to
variable conditions prior to procurement, which can impact on
cardiac recovery. Upon simulation of WLST, hearts developed
a hyperdynamic phase characterized by increased heart rate and
pulse pressure, whereas blood oxygen saturation and mean peak
systolic pressure continuously decreased. This hyperdynamic
phase was previously described in other preclinical models of
DCD (9, 10, 17). As the donor heart initially works under rapidly
developing hypotension and hypoxia, instantaneous systemic
responses to restore blood pressure are stimulated, including
catecholamine release. Accordingly, we detected increased
concentrations of catecholamines and circulating FFA in plasma
of rats at the end of the withdrawal, as well as the ischemic
phase. Besides influencing cardiac rhythm, contractility and
increasing intracranial pressure (28), catecholamines have been
shown in experimental settings to cause lactate accumulation,
ATP depletion, myocyte damage, and contraction band necrosis
(29, 30). Furthermore, catecholamines also trigger adaptations in
cardiac metabolism. Despite the tendency to decrease between
withdrawal of treatment and heart procurement, concentrations
of FFA remained high compared with physiologic values
(0.4mM) (31). Sympathetic stimulation induces lipolysis of
stored glycerides in adipocytes and increases concentrations of
circulating FFA. This is of particular importance as FFA have
been demonstrated to exacerbate reperfusion injury (22). Upon
reperfusion, as soon as oxygen is reintroduced to the tissue,
oxidation of FFA is stimulated and increases mitochondrial
ratios of NADH/NAD+ and acetyl-CoA/CoA, both of which
activate pyruvate dehydrogenase kinase. Activated pyruvate
dehydrogenase kinase inhibits pyruvate dehydrogenase, the rate
limiting enzyme of glucose oxidation. Reduced glucose oxidation
at the beginning of reperfusion results in uncoupling between
glycolysis and glucose oxidation and to a greater conversion
of pyruvate to lactate. Acidification of the cytoplasm can
further aggravate calcium overload and reperfusion injury (32).
Another cause of high concentrations of circulating FFA is
heparin. In DCD, heparin concentrations used are several times
higher compared with ordinary clinical anticoagulation (>300
units/kg vs. ∼80 units/kg) (33). Furthermore, in agreement with
other studies (34), heparinization was required in this model
to achieve effective heart reperfusion and prevent from clot
formation. In addition, heparin activates lipoprotein lipase at
the endothelial surface and stimulates the release of FFA from
circulating lipoproteins (31). Our results do not permit the
distinction between effects of heparinization and catecholamine
release on circulating FFA. However, as the circulating FFA
were already high during pre-withdrawal of life sustaining
therapy, when measured catecholamine concentrations were
very low, it is likely that initial free fatty acid release was
induced by heparin and that subsequent catecholamine-mediated
lipolysis was masked. Additionally, the increasing pattern of
catecholamines in parallel with the decreasing pattern of FFA
during the withdrawal phase also suggest that FFA release was
likely initially induced by heparin addition. It is technically
difficult to determine circulating FFA accurately in heparinized
blood as lipolysis may continue after sample collection, and an
overestimation in our samples of 20–50% can be expected (35).
However, taking this into consideration, the FFA levels measured
during the withdrawal period are still substantially higher than
physiologic levels.
As systemic changes during the withdrawal phase and
ischemia in situ can influence post-ischemic cardiac recovery,
it is essential that they are reflected in experimental models.
Over the last years, we developed an ex-situ model that
includes specific DCD-relevant conditions (3–6, 8) with, e.g.,
tight temperature control during warm ischemia and the
use of supraphysiologic perfusate FFA concentrations (1.2mM
palmitate) prior to ischemia. Nonetheless, some differences in
post-ischemic recovery between in-situ and ex-situmodels persist
and may be explained by systemic changes during withdrawal
and ischemia in situ. In general, post-ischemic recovery was
higher in the ex-situ vs. in-situmodel. In previous work with our
ex-situmodel, functional recovery deteriorated only significantly
after 27min ischemia, with a steep decline between 27 and
33min ischemia (5, 6). In the in-situmodel, before 27min FWIT
(starting with peak systolic pressure<50mmHg), the entire body
and heart are exposed to hypoxia during the withdrawal period
as demonstrated by low oxygen saturation, supraphysiologic
concentrations of circulating lactate and CO2 at FWIT. Pre-
ischemic hypoxia may be detrimental through the reduction of
ATP production via oxidative phosphorylation, in parallel with
increased lactate production and associated acidosis. It is known
that hypoxiamay also exert protective effects, as it could stimulate
pro-survival pathways activated by pre-conditioning; however,
these protocols generally require intermittent application by
several cycles of ischemia and reperfusion (36). Therefore, the
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TABLE 3 | Advantages and disadvantages of an ex-situ and in-situ ischemia model of DCD.
Advantages Disadvantages Suggested application
Ex-situ
ischemia model
Better control of experimental
conditions (e.g., pre-ischemic
conditions; clearly defined duration of
warm ischemia)
Relevance of findings need to be
evaluated in the context of scientific
question and clinical DCD conditions
Mechanistic studies investigating
pathophysiology of cardiac IRI or
molecular effects of therapeutic




Increased clinical relevance in the
context of DCD
Risk of increased variability due to
less tightly controlled conditions; no
consensus for start or end of FWIT in
clinical DCD protocols
Studies evaluating strategies to
improve aspects of DCD clinical
protocols such cardioprotection,
storage conditions or graft evaluation
DCD, donation after circulatory death; FWIT, functional warm ischemic time; IRI, ischemia-reperfusion injury.
additional exposure to hypoxia/ischemia could be a reason for
the lower post-ischemic recovery in IS vs. ES hearts. Further
damage may also result from increased levels of catecholamines,
as catecholamine storms have been associated with detrimental
organ function in brain dead donors (37, 38).
Although the cold, cardioplegic storage used in this study
adds a potentially damaging period of cold ischemia, our findings
indicate that it may provide some cardioprotection, potentially
via the cold, coronary flush and addition of protective agents.
Although not significantly different, tendencies for improved
contractile function and lower release of the cell death marker
cardiac troponin I were visible in IS+ vs. IS groups. EPO,
a component of the cardioplegia, has been shown to be
cardioprotective, through the activation of the pro-survival Akt
signaling pathway and decreased cell death (39–41). GTN is a
nitric oxide donor and a widely used drug to treat ischemic
heart disease (42). The addition of GTN and EPO in Celsior
cardioplegia was cardioprotective in rat and pig heart models
(43, 44). EPO and GTN may therefore contribute to the trend
of improved recovery in IS+ vs. IS hearts. Although we see
improved contractile function and reduced release of cell death
markers in IS+ vs. IS groups, cardioprotection could potentially
be further optimized with use of a preservation solution that is
better suited for DCD organs than St. Thomas’ N◦2, for example
with a normokalemic and hypocalcemic solution.
In this study, ischemia is associated with substantial changes
in coronary flow. In the absence of ischemia, coronary flow
at 5min reperfusion was higher in IS+ vs. ES hearts. This
higher coronary flow may result from the hyperemic response
since IS+ hearts were subjected to a short period of ischemia
during procurement and cannulation, and cold storage when
used, immediately prior to reperfusion. During ischemia, the
heart produces vasoactive compounds, such as adenosine, leading
to the vasodilation of the arterioles, the reduction of vascular
resistance and elevated coronary flow upon reperfusion, resulting
in hyperemia (45). Furthermore, with the cardioplegia, IS+
hearts received both GTN, a potent vasodilator via donation of
nitric oxide (46), and EPO, which has been shown to upregulate
endothelial nitric oxide synthase -derived nitric oxide production
by increasing phosphorylation and expression through PI3-
kinase/Akt (47). Thus, hyperemia, as well as GTN and EPO
supplementation, likely contribute to increased coronary flow
in IS+ vs. ES hearts in the absence of warm ischemia. Post-
ischemic coronary flow was significantly lower in IS and IS+ vs.
ES hearts at both early and late reperfusion time points. Although
the mechanism for this is not entirely clear, it is unlikely to
result from differences in edema-induced flow reductions since
all post-ischemic groups demonstrated similar levels of edema.
Contractile function tended to be greater in ES hearts, potentially
leading to a greater metabolic demand, which could stimulate
coronary flow. Alternatively, one might speculate that reductions
in coronary flow in IS and IS+ hearts may be a result of greater
exposure to adhesion molecules promoting platelet aggregates,
platelet-leukocyte aggregates and erythrocyte aggregates in hearts
undergoing ischemia in situ, which could block the capillaries and
lead to no-reflow (48).
Although the in-situ withdrawal period and ischemia
represent major differences from the ex-situ model, additional
differences are present between models that could influence
outcomes. For example, our in-situ model requires ante-mortem
heparinization, whereas no heparin was used in the ex-situ
model. Pre-ischemic heparin has been reported to reduce
ischemia-reperfusion injury in rabbit hearts (49, 50); however,
we generally observed reduced recovery in hearts exposed to
heparin. Furthermore, isolated heart preparations are recognized
to deteriorate with time (51) and our in-situ ischemia hearts
were maintained in the isolated system for approximately half the
time of those from the ex-situ model, which would be expected
to result in lower post-ischemic function in ES vs. IS and IS+
hearts, which is opposite to our observations. Lastly, due to
the ante-mortem surgical intervention (cannulation of carotid
artery), the anesthetic protocol for the in-situ model (ketamine,
xylazine, acepromazine) differs from that of the ex-situ model
(ketamine, xylazine).
Limitations
This study has several limitations. The models we used do
not account for neurologic injury, which is almost always
present in DCD donors, and could potentially lead to remote
preconditioning. In our in-situ model, WLST is simulated
by dissection of the animal’s diaphragm (asphyxiation model
of DCD), which may result in a shorter duration of the
period between WLST and circulatory arrest compared with
human DCD donors who may display remnants of spontaneous
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respiration (52). Additionally, due to the fact that rats did not
undergo intermittent positive pressure ventilation during general
anesthesia, hypercapnia and respiratory acidosis were present
before WLST, which can be avoided in human DCD donors. The
15-min cold static period implemented in the group of hearts
treated with St. Thomas’ N◦2 cardioplegic solution is a relatively
short period in the clinical setting for preparation of the heart
and/or the ex-situ perfusion machine. Future work could include
additional studies to better characterize the loss of myocardial
function in DCD by measuring, for example, infarct size; as well
as studies with increased sample size to confirm the relevance of
our results.
CONCLUSIONS
In this study, we characterized an in-situ rat model of DCD.
DCD grafts were subjected to hypoxia, hemodynamic changes,
acidosis, and increased concentrations of catecholamines and
circulating FFA before and during ischemia, which highlights the
suitability of this model for further research. In-situ conditions
were more detrimental for hearts vs. ex-situ conditions in
terms of post-ischemic contractility and relaxation rates, and
cardiac output. The application of cardioplegia tended to
abrogate differences compared to ES for cardiac function,
with the exception of cardiac output and coronary flow.
However, given the complexity of WLST and ischemia in
situ, future studies toward the optimization of clinical DCD
protocols will certainly benefit from preclinical models, which
incorporates the effects of systemic, and blood-borne changes
upon WLST.
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